Oral fluoropyrimidine S-1 combined with leucovorin is a promising therapy for colorectal cancer: Evidence from a xenograft model of folate-depleted mice

Molecular Medicine Reports

Volumn 2, Issue 3, 2009, Pages 393-398

  Tsukioka, Sayaka ^a   Uchida, Junji ^a   Tsujimoto, Hiroaki ^a   Nakagawa, Fumio ^a   Sugimoto, Yoshikazu ^a   Oka, Toshinori ^a   Kiniwa, Mamoru ^a  

^a TAIHO PHARMACEUTICAL CO LTD   (Japan)

Author keywords

5 fluorouracil; Leucovorin; Reduced folate; S 1; Thymidylate synthase

Indexed keywords

5 CHLORO 2,4 DIHYDROXYPYRIDINE PLUS OXONATE POTASSIUM PLUS TEGAFUR; FLOXURIDINE PHOSPHATE; FLUOROURACIL; FOLIC ACID; FOLINIC ACID; TERNARY COMPLEX FACTOR; THYMIDYLATE SYNTHASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER MODEL; COLORECTAL CANCER; CONTINUOUS INFUSION; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; DRUG POTENCY; DRUG POTENTIATION; ENZYME ACTIVITY; ENZYME INHIBITION; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VIVO STUDY; MALE; MONOTHERAPY; MOUSE; NONHUMAN; TISSUE LEVEL; TREATMENT DURATION; TREATMENT OUTCOME; TUMOR XENOGRAFT; WEIGHT REDUCTION;

MUS;

EID: 69249092231     PISSN: 17912997     EISSN: 17913004     Source Type: Journal    
DOI: 10.3892/mmr_00000111     Document Type: Article

References (28)

1. Douillard JY, Hoff PM, Skillings JR, Eisenberg P, Davidson N, Harper P, Vincent MD, Lembersky BC, Thompson S, Maniero A and Benner SE: Multicenter phase III study of uracil/tegafur and oral leucovorin versus fluorouracil and leucovorin in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 20: 3605-3616, 2002. (Pubitemid 34983220)
2. Carmichael J, Popiela T, Radstone D, Falk S, Borner M, Oza A, Skovsgaard T, Munier S and Martin C: Randomized comparative study of tegafur/uracil and oral leucovorin versus parenteral fluorouracil and leucovorin in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 20: 3617-3627, 2002. (Pubitemid 34983221)
3. Lembersky BC, Wieand HS, Petrelli NJ, O'Connell MJ, Colangelo LH, Smith RE, Seay TE, Giguere JK, Marshall ME, Jacobs AD, Colman LK, Soran A, Yothers G and Wolmark N: Oral uracil and tegafur plus leucovorin compared with intravenous fluorouracil and leucovorin in stage II and III carcinoma of the colon: results from National Surgical Adjuvant Breast and Bowel Project Protocol C-06. J Clin Oncol 24: 2059-2064, 2006. (Pubitemid 46622115)
4. Diasio RB: Clinical implications of dihydropyrimidine dehydrogenase inhibition. Oncology 13: 17-21, 1999.
5. Shirasaka T, Shimamato Y, Ohshimo H, Yamaguchi M, Kato T, Yonekura K and Fukushima M: Development of a novel form of an oral 5-fluorouracil derivative (S-1) directed to the potentiation of the tumor selective cytotoxicity of 5-fluorouracil by two biochemical modulators. Anticancer Drugs 7: 548-557, 1996. (Pubitemid 26276346)
6. Koizumi W, Narahara H, Hara T, Takagane A, Akiya T, Takagi M, Miyashita K, Nishizaki T, Kobayashi O, Takiyama W, Toh Y, Nagaie T, Takagi S, Yamamura Y, Yanaoka K, Orita H and Takeuchi M: S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial. Lancet Oncol 9: 215-221, 2008.
7. Ohtsu A, Baba H, Sakata Y, Mitachi Y, Horikoshi N, Sugimachi K and Taguchi T: Phase II study of S-1, a novel oral fluorophyrimidine derivative, in patients with metastatic colorectal carcinoma. S-1 Cooperative Colorectal Carcinoma Study Group. Br J Cancer 83: 141-145, 2000.
8. Danenberg PV, Langenbach RJ and Heidelberger C: Structures of reversible and irreversible complexes of thymidylate synthetase and fluorinated pyrimidine nucleotides. Biochemistry 13: 926-933, 1974.
9. Matherly LH, Czajkowski CA, Muench SP and Psiakis JT: Role for cytosolic folate-binding proteins in the compartmentation of endogenous tetrahydrofolates and the 5-formyl tetrahydrofolate-mediated enhancement of 5-fluoro-2′- deoxyuridine antitumor activity in vitro. Cancer Res 50: 3262-3269, 1990.
10. Park JG, Collins JM, Gazdar AF, Allegra CJ, Steinberg SM, Greene RF and Kramer BS: Enhancement of fluorinated pyrimidine-induced cytotoxicity by leucovorin in human colorectal carcinoma cell lines. J Natl Cancer Inst 80: 1560-1564, 1988.
11. Nadal JC, van Groeningen CJ, Pinedo HM and Peters GJ: In vivo potentiation of 5-fluorouracil by leucovorin in murine colon carcinoma. Biomed Pharmacother 42: 387-393, 1988.
12. Wright JE, Dreyfuss A, El-Magharbel I, Trites D, Jones SM, Holden SA, Rosowsky A and Frei E: Selective expansion of 5,10-methylenetetrahydrofolate pools and modulation of 5-fluorouracil antitumor activity by leucovorin in vivo. Cancer Res 49: 2592-2596, 1989. (Pubitemid 19143383)
13. Keyomarsi K and Moran RG: Folinic acid augmentation of the effects of fluoropyrimidines on murine and human leukemic cells. Cancer Res 46: 5229-5235, 1986. (Pubitemid 16008294)
14. Keyomarsi K and Moran RG: Mechanism of the cytotoxic synergism of fluoropyrimidines and folinic acid in mouse leukemic cells. J Biol Chem 263: 14402-14409, 1988. (Pubitemid 18244066)
15. Doroshow JH, Multhauf P, Leong L, et al: Prospective randomized comparison of fluorouracil versus fluorouracil and high-dose continuous infusion leucovorin calcium for the treatment of advanced measurable colorectal cancer in patients previously unexposed to chemotherapy. J Clin Oncol 8: 491-501, 1990. (Pubitemid 20087550)
16. Erlichman C, Fine S, Wong A and Elhakim T: A randomized trial of fluorouracil and folinic acid in patients with metastatic colorectal carcinoma. J Clin Oncol 6: 469-475, 1988. (Pubitemid 18090694)
17. Petrelli N, Douglass HO, Herrera L, et al: The modulation of fluorouracil with leucovorin in metastatic colorectal carcinoma: a prospective randomized phase III trial. Gastrointestinal Tumor Study Group. J Clin Oncol 7: 1419-1426, 1989. (Pubitemid 19245111)
18. Poon MA, O'Connell MJ, Moertel CG, et al: Biochemical modulation of fluorouracil: evidence of significant improvement of survival and quality of life in patients with advanced colorectal carcinoma. J Clin Oncol 7: 1407-1418, 1989.
19. Priest DG, Schmitz JC, Bunni MA and Stuart RK: Pharmacokinetics of leucovorin metabolites in human plasma as a function of dose administered orally and intravenously. J Natl Cancer Inst 83: 1806-1812, 1991.
20. Schmitz JC, Grindey GB, Schultz RM and Priest DG: Impact of dietary folic acid on reduced folates in mouse plasma and tissues. Relationship to dideazatetrahydrofolate sensitivity. Biochem Pharmacol 48: 319-325, 1994.
21. 4PteGlu assays. Adv Exp Med Biol 244: 97-106, 1988.
22. Spears CP, Gustavsson BG, Berne M, Frosing R, Bernstein L and Hayes AA: Mechanisms of innate resistance to thymidylate synthase inhibition after 5-fluorouracil. Cancer Res 48: 5894-5900, 1988. (Pubitemid 18248163)
23. Au JL and Sadée W: The pharmacology of ftorafur (R, S-1-(tetrahydro-2-furanyl)-5-fluorouracil. Recent Results Cancer Res 76: 100-114, 1981.
24. Houghton JA, Maroda SJ, Phillips JO and Houghton PJ: Biochemical determinants of responsiveness to 5-fluorouracil and its derivatives in xenografts of human colorectal adenocarcinomas in mice. Cancer Res 41: 144-149, 1981.
25. Lockshin A and Danenberg PV: Biochemical factors affecting the tightness of 5-fluorodeoxyuridylate binding to human thymidylate synthetase. Biochem Pharmacol 30: 247-257, 1981. (Pubitemid 11210738)
26. Danenberg PV and Danenberg KD: Effect of 5, 10-methylenetetrahydrofolate on the dissociation of 5-fluoro-2′-deoxyuridylate from thymidylate synthetase: evidence for an ordered mechanism. Biochemistry 17: 4018-4024, 1978.
27. Van der Wilt CL, Pinedo HM, Smid K and Peters GJ: Elevation of thymidylate synthase following 5-fluorouracil treatment is prevented by the addition of leucovorin in murine colon tumors. Cancer Res 52: 4922-4928, 1992.
28. Peters GJ, Backus HHJ, Freemantle S, van Triest B, Codacci-Pisanelli G, van der Wilt CL, Smid K, Lunec J, Calvert AH, Marsh S, McLeod HL, Bloemena E, Meijer S, Jansen G, van Groeningen CJ and Pinedo HM: Induction of thymidylate synthase as a 5-fluorouracil resistance mechanism. Biochim Biophys Acta 1587: 194-205, 2002. (Pubitemid 34655788)